Biopharmaceutical company Hansa Medical AB (STO:HMED) reported on Wednesday a change in the number of votes in the company as a result of conversion of in total 70,739 C shares into ordinary shares carried out in January 2018.
Reportedly, these conversion were carried out under Hansa Medical's long-term incentive programme.
As of 31 January 2018, the total number of registered and outstanding shares of Hansa Medical amounted to 38,208,386 of which 37,878,125 were ordinary shares, together carrying 37,878,125 votes, and 330,261 were C shares, together carrying 33,026.1 votes.
The total number of votes in Hansa Medical is 37,911,151.1.
Hansa Medical is developing novel immunomodulatory enzymes for transplantation and acute autoimmune diseases.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Innovent Biologics announces CFO transition
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial